SCHEMBL2144808

SCHEMBL2144808

CN(C)c1ccc(Nc2nc3cccc(NC4CCC(O)CC4)n3n2)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 2/20 0.40
BTK Q06187 2/20 0.39
MAP3K5 Q99683 1/20 0.38
KDM1A O60341 1/20 0.36
MAPKAPK2 P49137 1/20 0.36
PIM1 P11309 3/20 0.36
KCNH2 Q12809 2/20 0.36
FLT3 P36888 5/20 0.36
TYRO3 Q06418 4/20 0.36
MERTK Q12866 4/20 0.36
GAS6 Q14393 4/20 0.36
CCNT1 O60563 1/20 0.36
CDK9 P50750 1/20 0.36
KIT P10721 1/20 0.35
JAK2 O60674 1/20 0.35
JAK3 P52333 1/20 0.35
PTK2 Q05397 1/20 0.35
MAPK8 P45983 3/20 0.35
MAPK9 P45984 3/20 0.35
MAPK10 P53779 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2144800 1.00 FYN (0.40) FYNBTKMAP3K5KDM1AMAPKAPK2
SCHEMBL2144526 0.87 JUN (0.45) MAP3K5MAPKAPK2PIM1KCNH2FLT3
SCHEMBL2144535 0.87 JUN (0.45) MAP3K5MAPKAPK2PIM1KCNH2FLT3
SCHEMBL14457337 0.86 PIM1 (0.38) FYNMAP3K5MAPKAPK2PIM1KCNH2
SCHEMBL2144353 0.86 PIM1 (0.38) FYNMAP3K5MAPKAPK2PIM1KCNH2
SCHEMBL2144358 0.86 PIM1 (0.38) FYNMAP3K5MAPKAPK2PIM1KCNH2
SCHEMBL2144051 0.85 PIM1 (0.41) MAP3K5MAPKAPK2PIM1KCNH2FLT3
SCHEMBL2144041 0.85 PIM1 (0.41) MAP3K5MAPKAPK2PIM1KCNH2FLT3
SCHEMBL2144654 0.85 JAK2 (0.47) FYNBTKMAPKAPK2JAK2JAK3
SCHEMBL2144646 0.85 JAK2 (0.47) FYNBTKMAPKAPK2JAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344494-B1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARM LLC (US) 2016-04-20 EP claimed
US-20130005707-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BAHMANYAR SOGOLE (US) 2013-01-03 US claimed
US-8299056-B2 Aminotriazolopyridines, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC (US) 2012-10-30 US claimed
EP-2344494-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS Signal Pharmaceuticals, LLC (US) 2011-07-20 EP claimed
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2010-04-15 US claimed
WO-2010027500-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2010-03-11 WO claimed
EP-2344494-B1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARM LLC (US) 2016-04-20 EP disclosed
US-20130005707-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BAHMANYAR SOGOLE (US) 2013-01-03 US disclosed
US-8299056-B2 Aminotriazolopyridines, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC (US) 2012-10-30 US disclosed
EP-2344494-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS Signal Pharmaceuticals, LLC (US) 2011-07-20 EP disclosed
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2010-04-15 US disclosed
WO-2010027500-A1 AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005707-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 FYN 239/4885BTK 439/4885MAP3K5 5/4885
US-20100093698-A1 AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH MAP3K2, MAP3K1, MAP3K3 FYN 239/4885BTK 439/4885MAP3K5 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.